Medical cannabis reduced pain and improved sleep across rheumatology conditions

Patients with neuropathic problems reported the largest pain reduction (83%) and sleep improvement (87%), while those with inflammatory conditions saw the smallest pain reduction (57%). THC concentration, duration of use, and dosage each independently correlated with pain relief.

Cross-sectional phone survey of 351 rheumatology clinic patients licensed for medical cannabis in Israel. Patients reported pain reduction and sleep improvement. Researchers analyzed correlations between cannabis parameters and outcomes.

Rheumatology conditions like fibromyalgia are notoriously difficult to treat. This study captures real-world outcomes across multiple condition types within a single clinic population, offering a comparative snapshot of how different rheumatology patients respond to medical cannabis.

Self-reported outcomes this favorable need to be interpreted carefully, as patients who continue using cannabis are already a self-selected group. Still, the consistency of benefit across multiple rheumatology conditions suggests medical cannabis may have broad applicability in this patient population.

Cross-sectional design with no control group. Self-reported outcomes subject to recall and placebo effects. Survivorship bias: patients who stopped cannabis were not captured. No standardized pain or sleep measurement tools used.